Welcome to the Newsroom
22 November 2017
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces the grant of patent number2604275 entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the European Patent Office.
Article as pdf